Introduction
Tagrisso contains osimertinib, a prescription targeted anticancer medicine used in selected patients with EGFR-mutated non-small cell lung cancer (NSCLC). Correct administration is an important part of treatment because the medicine must be used according to the prescribed schedule and the applicable official prescribing information.
Tagrisso is available as an oral tablet, including the 80 mg strength featured on this website. The usual adult regimen described in official prescribing information is 80 mg taken once daily. However, the appropriate regimen and any necessary adjustments depend on the treatment indication, the patient’s clinical condition, tolerability and the advice of the treating oncology team.
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
The information below explains general administration principles. It is not an individualized prescription and must not be used to change a patient’s existing treatment plan.
What Is the Usual Tagrisso Dose?
The usual recommended adult dosage in official product information is 80 mg orally once daily for the relevant treatment indications.
The prescribed regimen may require modification if the patient develops certain adverse reactions or has other clinical circumstances requiring a change. Decisions about treatment interruption, dose reduction or discontinuation must be made by the treating healthcare professional in accordance with the applicable prescribing information.
Patients should not assume that the same dose is appropriate for every person with lung cancer. Treatment selection depends on the diagnosis, relevant EGFR mutation, disease stage, previous therapy and the specific indication for which osimertinib is being prescribed.
Available Strength and Dosage Form
The featured product is Tagrisso 80 mg, an oral tablet containing 80 mg of osimertinib.
| Product detail | Information |
|---|---|
| Brand name | Tagrisso |
| Generic name | Osimertinib |
| Featured strength | 80 mg |
| Dosage form | Oral tablet |
| Route of administration | Oral |
| Usual adult regimen in official prescribing information | 80 mg once daily |
| Treatment supervision | Qualified healthcare professional |
Product presentations can vary by market. Patients should confirm the actual strength and formulation on their packaging and follow the prescription issued for them.
The tablet strength indicates the amount of active ingredient in an individual tablet. It does not independently establish whether a patient should take one tablet, use a modified regimen or change treatment.
How Is Tagrisso Taken?
Tagrisso is administered by mouth according to the prescribed treatment schedule. Patients should follow the instructions supplied with their medicine and any additional guidance provided by their oncology team or pharmacist.
General principles include:
- Take the medicine according to the prescribed schedule.
- Follow the official patient leaflet for instructions about swallowing and administration.
- Do not change the prescribed dose independently.
- Do not take extra tablets to compensate for a missed dose.
- Ask a pharmacist or oncology professional if a tablet is damaged or if there is uncertainty about how to take it.
- Keep track of treatment and report problems with administration to the healthcare team.
Patients should not share their medicine with another person, even if that person has a similar diagnosis.
Should Tagrisso Be Taken With Food?
Food and administration instructions should be confirmed against the current official patient leaflet for the specific product being used. Patients should not rely on assumptions based on the administration requirements of other cancer medicines.
If the prescribing instructions permit administration regardless of meals, patients should follow those instructions consistently. If the product leaflet gives a specific direction, that direction should take priority.
Patients who experience nausea, difficulty swallowing or other problems with taking the tablet should seek advice from their oncology team or pharmacist rather than altering the medicine independently.
Swallowing and Handling the Tablet
Patients should follow the official administration instructions supplied with their product. They should not crush, chew, split or otherwise alter the tablet unless a qualified healthcare professional confirms that the proposed method is appropriate under the product instructions.
If a patient has difficulty swallowing tablets, the oncology team or pharmacist can review the approved administration options for the specific formulation.
Patients should avoid using damaged or unidentified tablets. If the tablet looks different from previous supplies, or the packaging appears compromised, they should ask a pharmacist to check the product before taking it.
Maintaining a Consistent Treatment Schedule
Consistent administration helps patients follow the prescribed treatment plan and makes it easier for the healthcare team to review possible adverse reactions.
Patients may find it helpful to use a written medication schedule or another suitable reminder method. The timing should remain consistent with the prescription and official product instructions.
If a dose is delayed, forgotten or taken incorrectly, the patient should consult the official patient leaflet or contact the oncology team for guidance. They should not take extra medicine simply to make up for a missed dose.
What Should I Do If I Miss a Dose?
A missed-dose situation should be managed according to the official instructions for Tagrisso.
Patients should not double the next dose to compensate for a missed tablet. The appropriate next step can depend on when the dose was missed and the specific instructions in the product information.
If the patient is uncertain, they should contact their pharmacist or oncology team before making changes to the schedule.
Patients should also tell their healthcare team if missed doses happen repeatedly because of side effects, difficulty remembering the schedule, problems obtaining the medicine or other practical barriers. The team may be able to help address the problem safely.
What If Vomiting Occurs After Taking Tagrisso?
Patients who vomit after taking a dose should not automatically take another tablet. They should follow the official patient leaflet or contact their healthcare professional for guidance about the appropriate next step.
Taking an additional tablet without guidance could result in an incorrect dose. The oncology team or pharmacist can explain how to handle the situation according to the applicable product instructions.
Treatment Interruptions and Dose Adjustments
Tagrisso can cause adverse reactions that sometimes require medical intervention. Depending on the nature and severity of the reaction, the prescribing clinician may recommend additional assessment, a temporary treatment interruption, a dose reduction or discontinuation.
Patients should not independently stop treatment or restart it after an interruption without professional guidance. They should promptly report significant symptoms and follow the instructions provided by their oncology team.
Treatment adjustments depend on the suspected adverse reaction, its severity, the patient’s overall condition and the relevant prescribing information.
Monitoring During Treatment
Monitoring helps the healthcare team evaluate treatment tolerance and identify complications.
Depending on the patient’s circumstances, monitoring may include:
- Review of new or worsening symptoms.
- Assessment of cough or breathing difficulties.
- Evaluation of heart-related symptoms and risk factors.
- Electrocardiography or electrolyte testing when clinically indicated.
- Assessment of possible cardiac dysfunction.
- Review of significant eye symptoms.
- Blood tests when indicated.
- Review of other medicines and possible interactions.
- Appropriate assessment of cancer response.
The precise monitoring schedule should be determined by the treating team. Patients should attend recommended appointments and report symptoms between appointments when necessary.
Side Effects That May Affect Administration
Possible adverse effects of Tagrisso include diarrhea, rash, dry skin, nail changes and mouth inflammation. Some patients may experience fatigue or other symptoms that interfere with daily activities.
Patients should tell their healthcare team about persistent diarrhea, difficulty drinking enough fluids, severe skin reactions, mouth problems that interfere with eating or other concerning effects.
Serious reactions can also occur, including interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy and eye complications. New or worsening breathing difficulties, fainting, an irregular heartbeat, chest symptoms or significant visual changes require prompt medical assessment.
Severe or rapidly worsening symptoms may require emergency medical care.
Drug Interactions and Other Medicines
Patients should tell their oncology team about all prescription medicines, nonprescription products, vitamins, supplements and herbal remedies they use.
Certain combinations may affect treatment safety or require additional precautions. Patients should not start a new medicine or supplement without checking whether it is appropriate during osimertinib treatment.
The healthcare team should also be informed about existing heart or lung conditions, previous serious medicine reactions and other relevant medical problems.
Storage and Handling
Patients should store Tagrisso according to the instructions on the product packaging and official patient leaflet. Medicines should be kept in their original packaging when appropriate, protected from unsuitable storage conditions and kept out of the reach of children.
Patients should check the expiry date and avoid using expired, damaged or unidentified tablets. They should ask a pharmacist how to dispose of unused medicine safely according to local requirements rather than sharing it or discarding it without guidance.
Frequently Asked Questions
Can I change the Tagrisso dose myself?
No. Any dose change or treatment interruption must be directed by a qualified healthcare professional.
Can I take extra tablets if I miss a dose?
Patients should not double a dose to compensate for a missed tablet. Follow the official patient leaflet or contact the oncology team for instructions.
Can I crush or chew Tagrisso tablets?
Follow the official administration instructions. Do not alter the tablet unless a qualified healthcare professional confirms an appropriate method for the specific product.
What should I do if I experience side effects?
Report persistent or concerning symptoms to the healthcare team. Seek urgent assessment for potentially serious symptoms such as breathing difficulties, fainting, an irregular heartbeat or significant visual changes.
Who determines the treatment schedule?
The treating oncology professional determines the appropriate regimen according to the indication, prescribing information and the patient’s clinical circumstances.
Conclusion
Correct administration of Tagrisso is an important part of safe treatment. Patients should follow their prescription, use the official product instructions, maintain communication with their healthcare team and report concerning symptoms promptly.
Medical Disclaimer: This page is for educational purposes only. It does not replace professional medical advice, diagnosis, treatment or official prescribing information. The appropriate dose and treatment schedule must be determined by a qualified healthcare professional. In a medical emergency, seek immediate assistance from local emergency medical services.